Purple Biotech says new U.S. patent allowance strengthens CAPTN-3 platform protection
Purple Biotech (PPBT) announced a U.S. patent allowance that strengthens protection for its CAPTN-3 modular platform for next-generation multispecific antibodies.
REHOVOT, Israel, Sept.
02, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the “Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer activity while minimizing toxicity, today announced that the…